Merck & Co., Inc. (NYSE:MRK – Get Free Report) released its earnings results on Tuesday. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.16 by $0.12, Briefing.com reports. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $16.10 billion for the quarter, compared to the consensus estimate of $15.87 billion. During the same quarter in the previous year, the firm earned ($2.06) earnings per share. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. Merck & Co., Inc. updated its FY 2024 guidance to 7.940-8.040 EPS and its FY24 guidance to $7.94-$8.04 EPS.
Merck & Co., Inc. Stock Down 0.3 %
Shares of MRK stock traded down $0.36 during mid-day trading on Wednesday, hitting $114.89. 5,515,137 shares of the stock traded hands, compared to its average volume of 8,465,479. The stock has a market cap of $290.99 billion, a P/E ratio of 128.01, a P/E/G ratio of 1.66 and a beta of 0.38. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The stock’s fifty day moving average is $127.75 and its two-hundred day moving average is $126.66. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63.
Merck & Co., Inc. Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 2.68%. The ex-dividend date is Monday, September 16th. Merck & Co., Inc.’s payout ratio is 342.22%.
Analyst Ratings Changes
Read Our Latest Stock Analysis on MRK
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More
- Five stocks we like better than Merck & Co., Inc.
- The 3 Best Fintech Stocks to Buy Now
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- What to Know About Investing in Penny Stocks
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.